LOCALIZED PROSTATE-CANCER TREATED BY EXTERNAL-BEAM RADIOTHERAPY ALONE - SERUM PROSTATE-SPECIFIC ANTIGEN-DRIVEN OUTCOME ANALYSIS

被引:110
作者
LEE, WR
HANKS, GE
SCHULTHEISS, TE
CORN, BW
HUNT, MA
机构
关键词
D O I
10.1200/JCO.1995.13.2.464
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Purpose: To determine the 5-year rate of survival with no evidence of disease (NED) using strict biochemical criteria in men with prostate cancer treated by external-beam radiotherapy alone and to examine possible clinical and treatment factors that predict the likelihood of NED survival. Materials and Methods: Five hundred men with clinically localized prostate cancer consecutively treated with external-beam radiotherapy alone with no prior, concomitant, or adjuvant endocrine therapy were identified. All patients had serial serum prostate-specific antigen (PSA) values determined after treatment and 451 patients had pretreatment PSA values determined. The median follow-up duration is 20 months (range, 2 to 72; mean, 36). Results: The 5-year rate of overall survival in this group of patients was 80%. The 5-year rate of survival without clinical evidence of disease (cNED) was 72%. The 5-year rate of survival without evidence of clinical, radiographic, or biochemical relapse (bNED) was 51%. Multivariate analysis demonstrated that a pretreatment serum PSA level less than or equal to 15 ng/mL was the most important predictor of bNED survival (P<.0001). Patients with early-stage (T1,T2a/b) tumors and a pretreatment serum PSA less than 15 ng/mL had a 9-year rate of bNED survival of 86%. The rate of bNED survival for patients with a pretreatment PSA level greater than 15 ng/mL was 38% at 3 years. Conclusion: Pretreatment serum PSA level is the most important predictor of treatment outcome in this group of patients treated with definitive radiotherapy alone. External-beam radiation alone can produce acceptable early rates of bNED survival in patients with clinically organ-confined tumors and a pretreatment PSA level less than or equal to 15 ng/mL. To produce acceptable results in those patients with pretreatment PSA levels more than 15 ng/mL, effective adjuvant treatments in addition to aggressive local treatments are necessary.
引用
收藏
页码:464 / 469
页数:6
相关论文
共 26 条
[1]
Bagshaw M A, 1988, NCI Monogr, P47
[2]
CANCER STATISTICS, 1993 [J].
BORING, CC ;
SQUIRES, TS ;
TONG, T .
CA-A CANCER JOURNAL FOR CLINICIANS, 1993, 43 (01) :7-26
[3]
IS PROSTATE SPECIFIC ANTIGEN OF CLINICAL IMPORTANCE IN EVALUATING OUTCOME AFTER RADICAL PROSTATECTOMY [J].
FRAZIER, HA ;
ROBERTSON, JE ;
HUMPHREY, PA ;
PAULSON, DF .
JOURNAL OF UROLOGY, 1993, 149 (03) :516-518
[4]
PROSTATIC-SPECIFIC ANTIGEN DOUBLING TIMES IN PATIENTS WITH PROSTATE-CANCER - A POTENTIALLY USEFUL REFLECTION OF TUMOR DOUBLING TIME [J].
HANKS, GE ;
DAMICO, A ;
EPSTEIN, BE ;
SCHULTHEISS, TE .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1993, 27 (01) :125-127
[5]
PSA CONFIRMATION OF CURE AT 10 YEARS OF T-1B, T-2, N-0, M(0) PROSTATE-CANCER PATIENTS TREATED IN RTOG PROTOCOL-7706 WITH EXTERNAL-BEAM IRRADIATION [J].
HANKS, GE ;
PEREZ, CA ;
KOZAR, M ;
ASBELL, SO ;
PILEPICH, MV ;
PAJAK, TF .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1994, 30 (02) :289-292
[6]
HANKS GE, 1993, INT J RADIAT ONCOL, V28, P39
[7]
HANKS GE, 1993, CANCER PRINCIPLES PR, P1073
[8]
CLINICAL USE OF PROSTATE SPECIFIC ANTIGEN IN PATIENTS WITH PROSTATE-CANCER [J].
HUDSON, MA ;
BAHNSON, RR ;
CATALONA, WJ .
JOURNAL OF UROLOGY, 1989, 142 (04) :1011-1017
[9]
KAPLAN ID, 1993, J UROLOGY, V149, P519, DOI 10.1016/S0022-5347(17)36133-5
[10]
KILLIAN CS, 1985, CANCER RES, V45, P886